{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005176","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.245234+00:00","generated_at":"2026-05-31T14:20:48.013074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance","bullets":["Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.","Adjusted EBITDA $2.24M, up 95.8% YoY; plasma revenue +12.6%, pharma patient affordability revenue +266.8%.","Added 8 net new plasma centers (477 total) and 8 net new patient affordability programs (61 total) in Q2.","FY 2024 revenue guidance raised to $56.5-$58.5M; adjusted EBITDA guided $9.0-$10.0M (15-17% of revenue).","Exited quarter with $31.29M unrestricted cash and zero debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005176","json":"https://secwatch.observer/filing/0001683168-24-005176.json","markdown":"https://secwatch.observer/filing/0001683168-24-005176.md","text":"https://secwatch.observer/filing/0001683168-24-005176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/0001683168-24-005176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:20:48.013074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}